SAN DIEGO, Sept. 16, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company dedicated to delivering high quality and novel medicines to physicians and patients at accessible prices, today announced that Chief Executive Officer Mark Baum will be a presenter at the 5th Annual Craig-Hallum Alpha Select Conference in New York City. Mr. Baum will discuss the company’s growth strategy, including its Go Dropless campaign in ophthalmology. The presentation is scheduled for 10:40 a.m. EST on Thursday, September 18, 2014 at the Convene Conference Center in New York. An audio portion of this presentation will be broadcast in a live webcast, and an archive of the webcast will be available for 90 days following the event. The webcast and slides for the presentation will be available at http://wsw.com/webcast/ch4/immy/ or on the Investor Relations section of the Imprimis’ website at www.imprimispharma.com.
Participation in the conference is by invitation only and will be held at Convene Midtown East at 730 3rd Avenue, 17th Floor, New York. Imprimis will also host one-on-one meetings and attendees can contact their Craig-Hallum representative or Imprimis to arrange a meeting.
ABOUT THE CRAIG-HALLUM ALPHA SELECT CONFERENCE
Entering its fifth year, The Craig-Hallum Alpha Select Conference has earned a reputation among clients as an important idea generation opportunity. Attending companies have been individually selected by the Craig-Hallum research team and are either currently on the Alpha Select List or display characteristics that are consistent with the Alpha Select List. For more information on the 5th Annual Craig-Hallum Alpha Select Conference, visit www.craig-hallum.com.
ABOUT IMPRIMIS PHARMACEUTICALS
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a San Diego-based specialty pharmaceutical company, is dedicated to delivering high quality and innovative medicines that address the unmet needs of physicians and patients at accessible prices. The company is currently focused on the development and commercialization of proprietary sterile and topical drug formulations for the ophthalmology and urology therapeutic markets, and recently launched its Go Dropless brand and physician education campaign. For more information, please visit www.imprimispharma.com and www.godropless.com.
SAFE HARBOR
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current expectations and assumptions and therefore are not guaranties of future performance and are subject to risks and uncertainties that may cause actual results to differ materially and adversely from those predicted by the forward looking statements. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis’ ability to make commercially available its compounded formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; including its ability to maintain compliance with applicable state and federal laws and regulations; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential markets for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. As a result of to these risks and uncertainties, undue reliance should not be placed on forward looking statements. You are encouraged to read Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, which more fully describe these and additional risks and uncertainties that may impact future performance. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. The limited information contained in this press release is not adequate for making an informed investment judgment. Forward looking statements speak only as of the date they are made and except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
For further information:
Media contact:
Amy Phillips
Pascale Communications, LLC
amy@pascalecommunications.com
cell: 412-327-9499
Investor contact:
Bonnie Ortega
Imprimis Pharmaceuticals
bortega@imprimispharma.com
office: 858.704.4587
SOURCE Imprimis Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
